CBD and Public-Speaking Anxiety: Subjective Improvement Was Not a Complete Physiological Response
A small randomized study found that a single CBD dose reduced some self-reported responses to a public-speaking challenge in people with social anxiety disorder. The physiological measures did not show corresponding significant between-group differences. Both findings belong in the interpretation.
A specific challenge in a specific population
Bergamaschi and colleagues randomized 24 never-treated patients with social anxiety disorder to 600 mg CBD or placebo, with 12 in each group. Another 12 healthy participants completed the simulated public-speaking test without receiving medication.
CBD was given 90 minutes before the challenge. Each participant attended one experimental session. This was human evidence about an acute, structured stressor, rather than a trial of long-term treatment, ordinary retail CBD use or whole-plant cannabis.
What improved, and what did not
During speech performance, the CBD group reported less anxiety, cognitive impairment and discomfort than the patient placebo group. Negative self-evaluation also increased less with CBD. The cognitive-impairment measure here was a subjective mood-scale factor, not an objective driving or neuropsychological performance test.
Blood pressure, heart rate and skin-conductance findings did not establish significant between-group physiological differences. Moreover, speech-phase anxiety in CBD-treated patients remained significantly different from the healthy comparison group. Describing every response as fully normalized would overstate the results.
Why the result remains preliminary
The small sample limits precision, and the unmedicated healthy comparison group is not another randomized treatment arm. Plasma CBD was not measured, so the investigators could not relate individual systemic exposure to reported effects.
The study also did not establish persistence of benefit, an optimal dosing range, or prevention of impairment during real-world activities. Its discussion called for larger trials and chronic-treatment research. Those questions cannot be resolved from an encouraging response during one laboratory speech.
When evaluating a therapeutic claim, identify the actual outcome and comparison before using words such as “effective” or “normal.” Our article on interpreting CBD treatment outcomes explains why study design and the definition of improvement materially affect a clinical conclusion.
Primary research
Mateus M Bergamaschi and colleagues. Neuropsychopharmacology (2011). Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients.
